FDA (CBER)
GUIDANCE DRAFT
Cross-Center Master Files: Where to Submit; Draft Guidance for Industry
Published: 11/24/2025Detected: 3/19/2026
Summary preview
Clarifies submission pathways for cross-center master files across various FDA centers, enhancing inter-center communication and efficiency.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
infectious_disease
manufacturing
#cross-center
#master files
#submission protocol
#FDA
#biologics
Official Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method9/16/2026
- Potency Assessment of Active Immunotherapy Products8/19/2026
- Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products: Guidance for Industry8/19/2026
- Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus: Guidance for Industry6/29/2026
- Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing6/2/2026